primaryid int64 82.9M 2.23B | caseid int64 8.29M 23.4M | caseversion int64 1 47 | i_f_code stringclasses 2
values | event_dt float64 20M 20.2M ⌀ | mfr_dt float64 20.2M 20.2M ⌀ | init_fda_dt stringdate 2011-12-14 00:00:00 2023-12-31 00:00:00 | fda_dt stringdate 2023-01-02 00:00:00 2023-12-31 00:00:00 | rept_cod stringclasses 5
values | auth_num stringclasses 98
values | mfr_num stringlengths 13 54 ⌀ | mfr_sndr stringclasses 138
values | lit_ref stringclasses 81
values | age float64 0 24.3k ⌀ | age_cod stringclasses 4
values | age_grp stringclasses 6
values | sex stringclasses 3
values | e_sub stringclasses 2
values | wt float64 2 245 ⌀ | wt_cod stringclasses 2
values | rept_dt stringdate 2022-12-21 00:00:00 2023-12-31 00:00:00 | to_mfr stringclasses 2
values | occp_cod stringclasses 5
values | reporter_country stringclasses 48
values | occr_country stringclasses 46
values | _quarter stringclasses 4
values | age_years float64 0 95 ⌀ | sex_label stringclasses 3
values | reporter_type stringclasses 5
values | report_type stringclasses 5
values | wt_kg float64 2 175 ⌀ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
220,353,541 | 22,035,354 | 1 | I | null | 20,230,215 | 2023-02-24 | 2023-02-24 | EXP | null | GB-TEVA-2023-GB-2859054 | TEVA | null | null | null | null | F | Y | null | null | 2023-02-24 | null | CN | GB | GB | 2023Q1 | null | Female | Consumer | Expedited | null |
228,582,071 | 22,858,207 | 1 | I | null | 20,230,813 | 2023-08-24 | 2023-08-24 | EXP | GB-MHRA-ADR 28117266 | GB-Accord-374140 | ACCORD | null | 22 | YR | A | M | Y | null | null | 2023-08-23 | null | HP | GB | GB | 2023Q3 | 22 | Male | Health professional | Expedited | null |
221,087,383 | 22,108,738 | 3 | F | 20,230,210 | 20,230,915 | 2023-03-17 | 2023-09-26 | EXP | null | US-PFIZER INC-PV202300044551 | PFIZER | null | 42 | YR | null | M | Y | 83.9 | KG | 2023-09-26 | null | HP | US | US | 2023Q3 | 42 | Male | Health professional | Expedited | 83.9 |
229,828,511 | 22,982,851 | 1 | I | null | 20,230,712 | 2023-09-26 | 2023-09-26 | EXP | null | US-ENDO-CASE-0015820 | ENDO | null | null | null | null | M | Y | null | null | 2023-09-26 | null | CN | US | null | 2023Q3 | null | Male | Consumer | Expedited | null |
233,113,001 | 23,311,300 | 1 | I | 20,231,207 | 20,231,208 | 2023-12-19 | 2023-12-19 | PER | null | US-ABBVIE-5537405 | ABBVIE | null | 45 | YR | null | M | Y | null | null | 2023-12-19 | null | CN | US | US | 2023Q4 | 45 | Male | Consumer | Periodic | null |
219,505,112 | 21,950,511 | 2 | F | 20,221,220 | 20,230,313 | 2023-02-03 | 2023-03-21 | EXP | null | US-UNITED THERAPEUTICS-UNT-2023-002468 | UNITED THERAPEUTICS | null | 73 | YR | null | F | Y | null | null | 2023-03-21 | null | CN | US | US | 2023Q1 | 73 | Female | Consumer | Expedited | null |
232,646,731 | 23,264,673 | 1 | I | null | 20,231,128 | 2023-12-05 | 2023-12-05 | EXP | null | CA-Nivagen-000067 | NIVAGEN PHARMACEUTICALS | CA-Nivagen-000067-01_Initial Source Document | 6 | DEC | A | F | Y | null | null | 2023-12-05 | null | HP | CA | null | 2023Q4 | 60 | Female | Health professional | Expedited | null |
223,423,211 | 22,342,321 | 1 | I | 20,230,418 | 20,230,511 | 2023-05-19 | 2023-05-19 | EXP | null | EG-Hikma Pharmaceuticals USA Inc.-EG-H14001-23-01560 | HIKMA | null | 51 | YR | null | F | Y | 84 | KG | 2023-05-19 | null | PH | EG | null | 2023Q2 | 51 | Female | Pharmacist | Expedited | 84 |
226,834,311 | 22,683,431 | 1 | I | null | 20,230,620 | 2023-07-07 | 2023-07-07 | PER | null | US-Dermavant-000713 | DERMAVANT SCIENCES | null | null | null | null | null | Y | null | null | 2023-07-07 | null | MD | US | US | 2023Q3 | null | Unknown | Physician | Periodic | null |
226,672,701 | 22,667,270 | 1 | I | 20,230,501 | 20,230,629 | 2023-07-04 | 2023-07-04 | PER | null | US-ELI_LILLY_AND_COMPANY-US202307000310 | ELI LILLY AND CO | null | 44 | YR | null | F | Y | null | null | 2023-07-04 | null | CN | US | US | 2023Q3 | 44 | Female | Consumer | Periodic | null |
219,812,231 | 21,981,223 | 1 | I | null | 20,230,202 | 2023-02-11 | 2023-02-11 | PER | GB-ROCHE-3275050 | GB-Shilpa Medicare Limited-SML-GB-2023-00162 | SHILPA MEDICARE | null | null | null | null | F | Y | null | null | 2023-02-11 | null | MD | GB | GB | 2023Q1 | null | Female | Physician | Periodic | null |
220,352,293 | 22,035,229 | 3 | F | 20,230,101 | 20,230,919 | 2023-02-24 | 2023-09-28 | PER | null | US-PFIZER INC-202200635595 | PFIZER | null | 67 | YR | null | F | Y | null | null | 2023-09-28 | null | CN | US | US | 2023Q3 | 67 | Female | Consumer | Periodic | null |
229,194,121 | 22,919,412 | 1 | I | null | 20,230,905 | 2023-09-08 | 2023-09-08 | PER | null | US-ELI_LILLY_AND_COMPANY-US202309002858 | ELI LILLY AND CO | null | null | null | null | M | Y | null | null | 2023-09-08 | null | CN | US | US | 2023Q3 | null | Male | Consumer | Periodic | null |
220,073,511 | 22,007,351 | 1 | I | 20,221,201 | 20,230,209 | 2023-02-18 | 2023-02-18 | EXP | null | FR-AUROBINDO-AUR-APL-2023-006788 | AUROBINDO | null | 27 | YR | null | M | Y | null | null | 2023-02-18 | null | PH | FR | FR | 2023Q1 | 27 | Male | Pharmacist | Expedited | null |
220,933,442 | 22,093,344 | 2 | F | null | 20,230,320 | 2023-03-14 | 2023-03-22 | PER | null | US-BRISTOL-MYERS SQUIBB COMPANY-2023-036944 | BRISTOL MYERS SQUIBB | null | 64 | YR | A | F | Y | null | null | 2023-03-22 | null | HP | US | US | 2023Q1 | 64 | Female | Health professional | Periodic | null |
219,557,881 | 21,955,788 | 1 | I | 20,230,113 | 20,230,115 | 2023-02-06 | 2023-02-06 | PER | null | HN-TOLMAR, INC.-23HN038473 | TOLMAR | null | 84 | YR | null | M | Y | null | null | 2023-02-06 | null | CN | HN | HN | 2023Q1 | 84 | Male | Consumer | Periodic | null |
219,906,781 | 21,990,678 | 1 | I | null | 20,230,209 | 2023-02-14 | 2023-02-14 | PER | null | US-PFIZER INC-202300062780 | PFIZER | null | null | null | A | F | Y | null | null | 2023-02-14 | null | HP | US | US | 2023Q1 | null | Female | Health professional | Periodic | null |
225,165,441 | 22,516,544 | 1 | I | 20,230,324 | 20,230,525 | 2023-06-03 | 2023-06-03 | EXP | null | IT-AUROBINDO-AUR-APL-2023-039318 | AUROBINDO | null | 54 | YR | null | F | Y | null | null | 2023-06-03 | null | HP | IT | IT | 2023Q2 | 54 | Female | Health professional | Expedited | null |
233,025,121 | 23,302,512 | 1 | I | 20,231,207 | 20,231,210 | 2023-12-15 | 2023-12-15 | EXP | GB-MHRA-TPP28898890C2567454YC1701952483501 | GB-PFIZER INC-202300441441 | PFIZER | null | 41 | YR | null | F | Y | 36 | KG | 2023-12-15 | null | MD | GB | GB | 2023Q4 | 41 | Female | Physician | Expedited | 36 |
221,740,322 | 22,174,032 | 2 | F | 20,230,301 | 20,230,420 | 2023-04-05 | 2023-05-04 | EXP | null | US-Santen Inc-2023-USA-002253 | SANTEN | null | null | null | null | F | Y | null | null | 2023-05-04 | null | CN | US | US | 2023Q2 | null | Female | Consumer | Expedited | null |
228,819,803 | 22,881,980 | 3 | F | 20,230,720 | 20,230,828 | 2023-08-30 | 2023-09-07 | EXP | null | NL-ASTELLAS-2023US025094 | ASTELLAS | null | 58 | YR | null | F | Y | null | null | 2023-09-07 | null | HP | NL | NL | 2023Q3 | 58 | Female | Health professional | Expedited | null |
227,048,171 | 22,704,817 | 1 | I | null | 20,230,706 | 2023-07-14 | 2023-07-14 | PER | null | US-JNJFOC-20230717755 | JOHNSON AND JOHNSON | null | null | null | A | F | Y | null | null | 2023-07-14 | null | MD | US | US | 2023Q3 | null | Female | Physician | Periodic | null |
219,908,472 | 21,990,847 | 2 | F | 20,200,108 | 20,230,221 | 2023-02-14 | 2023-03-01 | EXP | null | ES-VELOXIS PHARMACEUTICALS, INC.-2023-VEL-00085 | VELOXIS PHARMACEUTICALS | null | 70 | YR | null | F | Y | null | null | 2023-03-01 | null | MD | ES | ES | 2023Q1 | 70 | Female | Physician | Expedited | null |
229,936,822 | 22,993,682 | 2 | F | 20,230,821 | 20,231,103 | 2023-09-27 | 2023-11-10 | EXP | null | BR-ROCHE-3428667 | ROCHE | null | 75 | YR | null | M | Y | null | null | 2023-11-10 | null | HP | BR | BR | 2023Q4 | 75 | Male | Health professional | Expedited | null |
220,502,871 | 22,050,287 | 1 | I | null | 20,230,222 | 2023-03-01 | 2023-03-01 | PER | null | US-ELI_LILLY_AND_COMPANY-US202302011539 | ELI LILLY AND CO | null | 51 | YR | null | F | Y | null | null | 2023-03-01 | null | CN | US | US | 2023Q1 | 51 | Female | Consumer | Periodic | null |
226,936,011 | 22,693,601 | 1 | I | null | 20,230,628 | 2023-07-11 | 2023-07-11 | EXP | null | BG-EMD Serono-2023458677 | EMD SERONO INC | Grigorov N. METFORMIN INTOXICATION - THREE CLINICAL CASES WITH LETHAL OUTCOMES. RECOMMENDATIONS TO THE GENERAL PRACTITIONER. General Medicine. 2023;1:45-48. | 53 | YR | A | F | Y | null | null | 2023-07-11 | null | MD | BG | BG | 2023Q3 | 53 | Female | Physician | Expedited | null |
218,435,391 | 21,843,539 | 1 | I | null | null | 2023-01-09 | 2023-01-09 | DIR | 643953 | null | FDA-CTU | null | null | null | null | F | N | null | null | 2023-01-09 | Y | PH | US | null | 2023Q1 | null | Female | Pharmacist | Direct | null |
222,498,841 | 22,249,884 | 1 | I | 20,230,101 | 20,230,424 | 2023-04-25 | 2023-04-25 | PER | null | US-B.I. Pharmaceuticals,Inc./Ridgefield-2023-BI-233528 | BOEHRINGER INGELHEIM | null | 61 | YR | A | M | Y | null | null | 2023-04-25 | null | CN | US | US | 2023Q2 | 61 | Male | Consumer | Periodic | null |
223,872,914 | 22,387,291 | 4 | F | null | 20,230,711 | 2023-05-31 | 2023-07-21 | EXP | null | US-DECIPHERA PHARMACEUTICALS LLC-2023US000451 | DECIPHERA PHARMACEUTICALS | null | null | null | null | F | Y | null | null | 2023-07-21 | null | HP | US | US | 2023Q3 | null | Female | Health professional | Expedited | null |
2,105,825,610 | 21,058,256 | 10 | F | 20,220,706 | 20,230,623 | 2022-07-08 | 2023-06-23 | EXP | null | NVSC2022DE153914 | NOVARTIS | null | 30 | YR | null | F | Y | 65.4 | KG | 2023-06-23 | null | MD | DE | DE | 2023Q2 | 30 | Female | Physician | Expedited | 65.4 |
96,305,334 | 9,630,533 | 4 | F | 20,130,520 | 20,230,531 | 2013-10-18 | 2023-06-02 | EXP | null | GB-SHIRE-ALL1-2013-07010 | TAKEDA | null | 8 | YR | null | M | Y | 25 | KG | 2023-06-02 | null | MD | GB | GB | 2023Q2 | 8 | Male | Physician | Expedited | 25 |
222,101,262 | 22,210,126 | 2 | F | null | 20,230,707 | 2023-04-14 | 2023-07-13 | PER | null | US-SA-2023SA113957 | SANOFI AVENTIS | null | null | null | A | F | Y | null | null | 2023-07-13 | null | MD | US | US | 2023Q3 | null | Female | Physician | Periodic | null |
232,657,011 | 23,265,701 | 1 | I | null | 20,231,204 | 2023-12-06 | 2023-12-06 | EXP | null | NVSC2023US258598 | NOVARTIS | null | null | null | null | M | Y | null | null | 2023-12-06 | null | MD | US | US | 2023Q4 | null | Male | Physician | Expedited | null |
218,558,341 | 21,855,834 | 1 | I | null | 20,230,109 | 2023-01-12 | 2023-01-12 | EXP | null | CA-GILEAD-2023-0612260 | GILEAD | null | 66 | YR | E | F | Y | null | null | 2023-01-12 | null | CN | CA | CA | 2023Q1 | 66 | Female | Consumer | Expedited | null |
223,922,151 | 22,392,215 | 1 | I | 20,190,101 | 20,230,519 | 2023-06-01 | 2023-06-01 | EXP | null | US-SUN PHARMACEUTICAL INDUSTRIES LTD-2023R1-390572 | RANBAXY | null | null | null | null | null | Y | null | null | 2023-06-01 | null | LW | US | US | 2023Q2 | null | Unknown | Lawyer | Expedited | null |
219,363,871 | 21,936,387 | 1 | I | 20,221,027 | 20,230,127 | 2023-02-01 | 2023-02-01 | EXP | FR-AFSSAPS-RN20223067 | FR-MYLANLABS-2023M1010517 | MYLAN | null | 73 | YR | null | M | Y | null | null | 2023-02-01 | null | CN | FR | FR | 2023Q1 | 73 | Male | Consumer | Expedited | null |
231,511,543 | 23,151,154 | 3 | F | 20,230,101 | 20,231,201 | 2023-11-06 | 2023-12-07 | EXP | null | US-ABBVIE-5483158 | ABBVIE | null | null | null | null | M | Y | null | null | 2023-12-07 | null | CN | US | US | 2023Q4 | null | Male | Consumer | Expedited | null |
230,684,273 | 23,068,427 | 3 | F | 20,230,801 | 20,231,122 | 2023-10-16 | 2023-12-12 | 30DAY | null | CL-PFIZER INC-PV202300159366 | PFIZER | null | 12 | YR | null | M | Y | null | null | 2023-12-12 | null | CN | CL | CL | 2023Q4 | 12 | Male | Consumer | 30DAY | null |
233,438,011 | 23,343,801 | 1 | I | 20,231,208 | 20,231,212 | 2023-12-27 | 2023-12-27 | EXP | null | US-HLS-202302091 | HLS THERAPEUTICS | null | 54 | YR | A | M | Y | null | null | 2023-12-27 | null | CN | US | US | 2023Q4 | 54 | Male | Consumer | Expedited | null |
216,642,494 | 21,664,249 | 4 | F | null | 20,230,501 | 2022-11-30 | 2023-05-05 | PER | null | NVSC2022US278308 | NOVARTIS | null | null | null | null | F | Y | null | null | 2023-05-05 | null | CN | US | US | 2023Q2 | null | Female | Consumer | Periodic | null |
228,172,541 | 22,817,254 | 1 | I | 20,230,517 | 20,230,802 | 2023-08-12 | 2023-08-12 | 30DAY | null | US-GSK-US2023105250 | GLAXOSMITHKLINE | null | 70 | YR | null | F | Y | null | null | 2023-08-12 | null | CN | US | US | 2023Q3 | 70 | Female | Consumer | 30DAY | null |
218,530,851 | 21,853,085 | 1 | I | null | 20,221,209 | 2023-01-12 | 2023-01-12 | PER | null | US-ABBVIE-4231702 | ABBVIE | null | null | null | null | F | Y | null | null | 2023-01-12 | null | CN | US | US | 2023Q1 | null | Female | Consumer | Periodic | null |
228,675,101 | 22,867,510 | 1 | I | null | 20,230,822 | 2023-08-25 | 2023-08-25 | EXP | null | US-PFIZER INC-PV202300144922 | PFIZER | null | 27 | YR | null | F | Y | null | null | 2023-08-25 | null | HP | US | US | 2023Q3 | 27 | Female | Health professional | Expedited | null |
232,839,231 | 23,283,923 | 1 | I | null | 20,231,204 | 2023-12-11 | 2023-12-11 | PER | null | US-BRISTOL-MYERS SQUIBB COMPANY-2023-176027 | BRISTOL MYERS SQUIBB | Zabel KM, Tagliaferro-Epler L, Ho C, Tafoya M, Reyes M, Vashistha V. A case series of rare immune-mediated adverse reactions at the new Mexico veterans affairs medical center. Federal Practitioner. 2023 Aug 21;40(Suppl 3):S62-7.doi:10.12788/fp.0398. | 84 | YR | E | M | Y | null | null | 2023-12-11 | null | MD | US | US | 2023Q4 | 84 | Male | Physician | Periodic | null |
227,695,183 | 22,769,518 | 3 | F | null | 20,230,927 | 2023-08-01 | 2023-10-03 | PER | null | US-UNITED THERAPEUTICS-UNT-2023-021045 | UNITED THERAPEUTICS | null | null | null | null | F | Y | 104.31 | KG | 2023-10-03 | null | CN | US | US | 2023Q4 | null | Female | Consumer | Periodic | 104.3 |
230,492,301 | 23,049,230 | 1 | I | null | null | 2023-10-06 | 2023-10-06 | DIR | FDA-CDER-CTU-2023-73978 | null | FDA-CTU | null | 49 | YR | null | F | N | null | null | 2023-10-06 | N | null | US | null | 2023Q4 | 49 | Female | null | Direct | null |
221,848,231 | 22,184,823 | 1 | I | 20,230,310 | 20,230,331 | 2023-04-07 | 2023-04-07 | EXP | NO-NOMAADVRE-RELISN-2023-Vpdbbb | NO-009507513-2304NOR000031 | MERCK | null | 80 | YR | null | F | Y | null | null | 2023-04-07 | null | MD | NO | NO | 2023Q2 | 80 | Female | Physician | Expedited | null |
230,674,233 | 23,067,423 | 3 | F | 20,230,701 | 20,231,025 | 2023-10-16 | 2023-10-31 | EXP | null | CO-GSK-CO2023AMR106201 | GLAXOSMITHKLINE | null | null | null | null | null | Y | null | null | 2023-10-31 | null | CN | CO | CO | 2023Q4 | null | Unknown | Consumer | Expedited | null |
229,453,351 | 22,945,335 | 1 | I | null | 20,230,911 | 2023-09-14 | 2023-09-14 | PER | null | JP-PFIZER INC-202300296918 | PFIZER | null | null | null | null | null | Y | null | null | 2023-09-14 | null | PH | JP | JP | 2023Q3 | null | Unknown | Pharmacist | Periodic | null |
232,564,292 | 23,256,429 | 2 | F | null | 20,230,829 | 2023-12-04 | 2023-12-20 | EXP | null | US-AMNEAL PHARMACEUTICALS-2023-AMRX-02767 | AMNEAL | null | null | null | null | F | Y | null | null | 2023-12-14 | null | CN | US | US | 2023Q4 | null | Female | Consumer | Expedited | null |
223,388,161 | 22,338,816 | 1 | I | null | 20,230,503 | 2023-05-18 | 2023-05-18 | EXP | null | CN-SUN PHARMACEUTICAL INDUSTRIES LTD-2023R1-388511 | RANBAXY | Cheng T, Liu J, Sun W, Song G, Ma H. Congenital adrenal hyperplasia with homozygous and heterozygous mutations: a rare family case report. BMC Endocr Disord. 2022;22(1):57; 1-9 | 31 | YR | null | F | Y | null | null | 2023-05-18 | null | HP | CN | CN | 2023Q2 | 31 | Female | Health professional | Expedited | null |
220,816,842 | 22,081,684 | 2 | F | 20,221,114 | 20,230,309 | 2023-03-10 | 2023-03-17 | EXP | null | BR-CELLTRION INC.-2022BR015882 | CELLTRION | null | null | null | null | null | Y | null | null | 2023-03-17 | null | CN | BR | BR | 2023Q1 | null | Unknown | Consumer | Expedited | null |
219,770,152 | 21,977,015 | 2 | F | null | 20,230,913 | 2023-02-10 | 2023-09-19 | PER | null | NVSC2023US025362 | NOVARTIS | null | null | null | null | F | Y | null | null | 2023-09-19 | null | CN | US | US | 2023Q3 | null | Female | Consumer | Periodic | null |
229,326,572 | 22,932,657 | 2 | F | 20,230,505 | 20,230,914 | 2023-09-12 | 2023-09-15 | EXP | null | CN-BIOVITRUM-2023-CN-014729 | BIOVITRUM | null | 63 | YR | null | F | Y | null | null | 2023-09-15 | null | HP | CN | CN | 2023Q3 | 63 | Female | Health professional | Expedited | null |
226,039,001 | 22,603,900 | 1 | I | null | 20,230,613 | 2023-06-15 | 2023-06-15 | EXP | null | US-UCBSA-2023029933 | UCB | null | null | null | null | F | Y | null | null | 2023-06-15 | null | HP | US | US | 2023Q2 | null | Female | Health professional | Expedited | null |
228,437,304 | 22,843,730 | 4 | F | 20,230,701 | 20,231,205 | 2023-08-21 | 2023-12-12 | EXP | null | JP-ARGENX-2023-ARGX-JP000812 | ARGENX BVBA | null | null | null | null | null | Y | null | null | 2023-12-12 | null | MD | JP | JP | 2023Q4 | null | Unknown | Physician | Expedited | null |
232,467,791 | 23,246,779 | 1 | I | null | 20,231,121 | 2023-11-30 | 2023-11-30 | PER | null | US-SA-2023SA368187 | SANOFI AVENTIS | null | 37 | YR | A | F | Y | null | null | 2023-11-30 | null | MD | US | US | 2023Q4 | 37 | Female | Physician | Periodic | null |
217,027,283 | 21,702,728 | 3 | F | 20,221,202 | 20,230,110 | 2022-12-09 | 2023-01-16 | PER | null | US-AMGEN-USASP2022210545 | AMGEN | null | 56 | YR | A | F | Y | 109.75 | KG | 2023-01-16 | null | PH | US | US | 2023Q1 | 56 | Female | Pharmacist | Periodic | 109.8 |
221,710,331 | 22,171,033 | 1 | I | 20,230,322 | 20,230,322 | 2023-04-04 | 2023-04-04 | PER | null | US-JNJFOC-20230362055 | JOHNSON AND JOHNSON | null | null | null | null | M | Y | null | null | 2023-04-04 | null | CN | US | US | 2023Q2 | null | Male | Consumer | Periodic | null |
223,383,921 | 22,338,392 | 1 | I | 20,220,301 | 20,230,516 | 2023-05-18 | 2023-05-18 | EXP | null | CN-GILEAD-2023-0619990 | GILEAD | null | 46 | YR | A | M | Y | null | null | 2023-05-18 | null | MD | CN | CN | 2023Q2 | 46 | Male | Physician | Expedited | null |
230,668,501 | 23,066,850 | 1 | I | 20,230,101 | 20,231,006 | 2023-10-16 | 2023-10-16 | PER | null | US-SA-2023SA308489 | SANOFI AVENTIS | null | 18 | YR | A | M | Y | null | null | 2023-10-16 | null | MD | US | US | 2023Q4 | 18 | Male | Physician | Periodic | null |
233,071,321 | 23,307,132 | 1 | I | null | 20,231,212 | 2023-12-18 | 2023-12-18 | PER | null | NVSC2023US267831 | NOVARTIS | null | null | null | null | M | Y | 97.98 | KG | 2023-12-18 | null | CN | US | US | 2023Q4 | null | Male | Consumer | Periodic | 98 |
218,527,771 | 21,852,777 | 1 | I | null | 20,221,212 | 2023-01-12 | 2023-01-12 | PER | null | US-ABBVIE-4236863 | ABBVIE | null | null | null | null | F | Y | null | null | 2023-01-12 | null | CN | US | US | 2023Q1 | null | Female | Consumer | Periodic | null |
227,957,741 | 22,795,774 | 1 | I | 20,230,101 | 20,230,801 | 2023-08-07 | 2023-08-07 | PER | null | US-JNJFOC-20230806581 | JOHNSON AND JOHNSON | null | 35 | YR | A | F | Y | null | null | 2023-08-07 | null | CN | US | US | 2023Q3 | 35 | Female | Consumer | Periodic | null |
222,240,581 | 22,224,058 | 1 | I | null | 20,230,412 | 2023-04-18 | 2023-04-18 | EXP | null | DE-MYLANLABS-2023M1040033 | MYLAN | null | 32 | YR | null | F | Y | 75 | KG | 2023-04-18 | null | MD | DE | DE | 2023Q2 | 32 | Female | Physician | Expedited | 75 |
229,571,821 | 22,957,182 | 1 | I | null | 20,230,911 | 2023-09-19 | 2023-09-19 | PER | null | CH-ALM-HQ-CH-2023-2173 | ALMIRALL | null | null | null | E | F | Y | null | null | 2023-09-19 | null | HP | CH | CH | 2023Q3 | null | Female | Health professional | Periodic | null |
229,881,601 | 22,988,160 | 1 | I | null | 20,230,914 | 2023-09-26 | 2023-09-26 | EXP | null | US-BAYER-2023A130086 | BAYER | null | null | null | null | null | Y | null | null | 2023-09-26 | null | HP | US | US | 2023Q3 | null | Unknown | Health professional | Expedited | null |
222,497,412 | 22,249,741 | 2 | F | 20,190,516 | 20,230,531 | 2023-04-25 | 2023-06-05 | EXP | null | GB-MYLANLABS-2023M1042454 | MYLAN | null | 47 | YR | null | M | Y | null | null | 2023-06-05 | null | MD | GB | GB | 2023Q2 | 47 | Male | Physician | Expedited | null |
233,525,651 | 23,352,565 | 1 | I | null | 20,231,215 | 2023-12-30 | 2023-12-30 | EXP | null | IT-ACI HealthCare Limited-2149960 | ACI HEALTHCARE | Terranova C, Massaro L, Angiola F. An unusual unplanned complex suicide by arm cutting, poisoning, and self-immolation. Forensic Science International: Reports 8: no pagination, Dec 2023.https://www.journals.elsevier.com/forensic-science-international-reports | 67 | YR | null | F | Y | null | null | 2023-12-30 | null | HP | IT | IT | 2023Q4 | 67 | Female | Health professional | Expedited | null |
229,445,341 | 22,944,534 | 1 | I | null | 20,230,907 | 2023-09-14 | 2023-09-14 | EXP | null | CA-AstraZeneca-2023A197999 | ASTRAZENECA | null | null | null | null | F | Y | null | null | 2023-09-14 | null | MD | CA | null | 2023Q3 | null | Female | Physician | Expedited | null |
226,414,012 | 22,641,401 | 2 | F | null | 20,230,816 | 2023-06-26 | 2023-08-21 | PER | null | US-BIOGEN-2023BI01212426 | BIOGEN | null | null | null | null | F | Y | null | null | 2023-08-21 | null | HP | US | US | 2023Q3 | null | Female | Health professional | Periodic | null |
218,213,741 | 21,821,374 | 1 | I | null | 20,221,129 | 2023-01-05 | 2023-01-05 | PER | null | US-ABBVIE-4217780 | ABBVIE | null | null | null | null | M | Y | null | null | 2023-01-05 | null | CN | US | US | 2023Q1 | null | Male | Consumer | Periodic | null |
218,607,321 | 21,860,732 | 1 | I | 20,230,102 | 20,230,110 | 2023-01-13 | 2023-01-13 | PER | null | US-JNJFOC-20230123424 | JOHNSON AND JOHNSON | null | 41 | YR | A | F | Y | null | null | 2023-01-13 | null | HP | US | US | 2023Q1 | 41 | Female | Health professional | Periodic | null |
221,078,221 | 22,107,822 | 1 | I | null | 20,230,313 | 2023-03-17 | 2023-03-17 | EXP | null | US-ROCHE-3309344 | ROCHE | Garcia J, Zia A Serious Breakthrough Bleed in Patients with Severe Hemophilia A With and Without an Inhibitor in Emicizumab Prophylaxis. Congress Poster ;:1-. | 12 | YR | null | null | Y | null | null | 2023-03-17 | null | MD | US | null | 2023Q1 | 12 | Unknown | Physician | Expedited | null |
227,967,143 | 22,796,714 | 3 | F | null | 20,230,925 | 2023-08-08 | 2023-10-01 | PER | null | US-AMGEN-USASP2023138061 | AMGEN | null | 62 | YR | A | F | Y | null | null | 2023-10-01 | null | HP | US | US | 2023Q4 | 62 | Female | Health professional | Periodic | null |
220,111,711 | 22,011,171 | 1 | I | 20,230,212 | 20,230,216 | 2023-02-20 | 2023-02-20 | PER | null | US-BRISTOL-MYERS SQUIBB COMPANY-2023-024910 | BRISTOL MYERS SQUIBB | null | 29 | YR | A | F | Y | null | null | 2023-02-20 | null | HP | US | US | 2023Q1 | 29 | Female | Health professional | Periodic | null |
225,283,922 | 22,528,392 | 2 | F | null | 20,230,604 | 2023-06-07 | 2023-06-12 | PER | null | NVSC2023US129220 | NOVARTIS | null | null | null | null | F | Y | null | null | 2023-06-12 | null | CN | US | US | 2023Q2 | null | Female | Consumer | Periodic | null |
232,613,491 | 23,261,349 | 1 | I | 20,231,127 | 20,231,127 | 2023-12-05 | 2023-12-05 | 30DAY | null | US-GSK-US2023165368 | GLAXOSMITHKLINE | null | 67 | YR | null | F | Y | null | null | 2023-12-05 | null | MD | US | US | 2023Q4 | 67 | Female | Physician | 30DAY | null |
231,664,001 | 23,166,400 | 1 | I | null | 20,230,713 | 2023-11-09 | 2023-11-09 | EXP | null | US-ENDO-CASE-0039961 | ENDO | null | null | null | null | null | Y | null | null | 2023-11-09 | null | CN | US | null | 2023Q4 | null | Unknown | Consumer | Expedited | null |
227,471,261 | 22,747,126 | 1 | I | 20,230,701 | 20,230,724 | 2023-07-25 | 2023-07-25 | PER | null | US-BRISTOL-MYERS SQUIBB COMPANY-2023-104565 | BRISTOL MYERS SQUIBB | null | 79 | YR | E | F | Y | 66.5 | KG | 2023-07-25 | null | PH | US | US | 2023Q3 | 79 | Female | Pharmacist | Periodic | 66.5 |
230,289,611 | 23,028,961 | 1 | I | null | 20,230,929 | 2023-10-04 | 2023-10-04 | PER | null | US-BRISTOL-MYERS SQUIBB COMPANY-2023-140221 | BRISTOL MYERS SQUIBB | null | 73 | YR | E | M | Y | null | null | 2023-10-04 | null | HP | US | US | 2023Q4 | 73 | Male | Health professional | Periodic | null |
231,418,671 | 23,141,867 | 1 | I | 20,230,927 | 20,230,928 | 2023-11-03 | 2023-11-03 | PER | null | US-MYOVANT SCIENCES GMBH-2023MYSCI0901000 | MYOVANT SCIENCES | null | 62 | YR | null | M | Y | null | null | 2023-11-03 | null | CN | US | US | 2023Q4 | 62 | Male | Consumer | Periodic | null |
225,329,831 | 22,532,983 | 1 | I | null | 20,230,515 | 2023-06-07 | 2023-06-07 | PER | null | US-GALDERMA-US2023007723 | GALDERMA | null | null | null | null | null | Y | null | null | 2023-06-07 | null | CN | US | US | 2023Q2 | null | Unknown | Consumer | Periodic | null |
225,860,891 | 22,586,089 | 1 | I | null | 20,230,527 | 2023-06-10 | 2023-06-10 | EXP | null | IN-SUN PHARMACEUTICAL INDUSTRIES LTD-2023R1-394067 | RANBAXY | Gn D, Patil M, Shafiq S. Drug-induced bradycardia. Clin Med. 2023;23(2):173-174 | 45 | YR | null | F | Y | null | null | 2023-06-10 | null | HP | IN | IN | 2023Q2 | 45 | Female | Health professional | Expedited | null |
228,670,871 | 22,867,087 | 1 | I | 20,230,821 | 20,230,822 | 2023-08-25 | 2023-08-25 | PER | null | US-AMGEN-USASP2023148881 | AMGEN | null | 79 | YR | E | F | Y | null | null | 2023-08-25 | null | HP | US | US | 2023Q3 | 79 | Female | Health professional | Periodic | null |
219,287,325 | 21,928,732 | 5 | F | 20,230,101 | 20,230,823 | 2023-01-31 | 2023-08-29 | EXP | null | CO-AMGEN-COLSP2023015798 | AMGEN | null | 58 | YR | A | F | Y | null | null | 2023-08-29 | null | CN | CO | CO | 2023Q3 | 58 | Female | Consumer | Expedited | null |
231,287,801 | 23,128,780 | 1 | I | null | 20,231,020 | 2023-10-31 | 2023-10-31 | EXP | null | MY-TAKEDA-2023TUS104504 | TAKEDA | null | 52 | YR | null | M | Y | null | null | 2023-10-31 | null | CN | MY | MY | 2023Q4 | 52 | Male | Consumer | Expedited | null |
228,314,571 | 22,831,457 | 1 | I | null | 20,230,814 | 2023-08-17 | 2023-08-17 | PER | null | NVSC2023US178145 | NOVARTIS | null | null | null | null | F | Y | null | null | 2023-08-17 | null | CN | US | US | 2023Q3 | null | Female | Consumer | Periodic | null |
226,363,221 | 22,636,322 | 1 | I | 20,230,526 | 20,230,620 | 2023-06-23 | 2023-06-23 | EXP | null | US-ABBVIE-5300744 | ABBVIE | null | 74 | YR | null | M | Y | null | null | 2023-06-23 | null | CN | US | US | 2023Q2 | 74 | Male | Consumer | Expedited | null |
220,783,641 | 22,078,364 | 1 | I | null | null | 2023-03-08 | 2023-03-08 | DIR | FDA-CDER-CTU-2023-18600 | null | FDA-CTU | null | null | null | null | null | N | null | null | 2023-01-31 | N | PH | US | null | 2023Q1 | null | Unknown | Pharmacist | Direct | null |
227,399,671 | 22,739,967 | 1 | I | 20,230,216 | 20,230,718 | 2023-07-23 | 2023-07-23 | EXP | null | NVSC2023EG161363 | NOVARTIS | null | 65 | YR | null | M | Y | null | null | 2023-07-23 | null | MD | EG | EG | 2023Q3 | 65 | Male | Physician | Expedited | null |
225,404,511 | 22,540,451 | 1 | I | null | 20,230,531 | 2023-06-09 | 2023-06-09 | EXP | null | US-APOTEX-2023AP008873 | APOTEX | Comstock G, Kaiser S, Heard K, Wang GS. Significance of temperature in antimuscarinic toxicity: a case-control study. CLINICAL TOXICOLOGY. 2022;60 (9):1070-1072 | null | null | T | null | Y | null | null | 2023-06-09 | null | HP | US | US | 2023Q2 | null | Unknown | Health professional | Expedited | null |
227,619,101 | 22,761,910 | 1 | I | null | 20,230,719 | 2023-07-28 | 2023-07-28 | PER | null | US-PFIZER INC-202300256223 | PFIZER | null | 68 | YR | null | F | Y | null | null | 2023-07-28 | null | MD | US | US | 2023Q3 | 68 | Female | Physician | Periodic | null |
227,770,091 | 22,777,009 | 1 | I | 20,230,726 | 20,230,726 | 2023-08-02 | 2023-08-02 | PER | null | US-SA-2023SA231503 | SANOFI AVENTIS | null | 72 | YR | E | M | Y | null | null | 2023-08-02 | null | MD | US | US | 2023Q3 | 72 | Male | Physician | Periodic | null |
231,719,431 | 23,171,943 | 1 | I | 20,231,024 | 20,231,103 | 2023-11-10 | 2023-11-10 | EXP | null | CN-AstraZeneca-2023A253679 | ASTRAZENECA | null | 4,017 | DY | null | F | Y | 31 | KG | 2023-11-10 | null | MD | CN | null | 2023Q4 | 11 | Female | Physician | Expedited | 31 |
227,213,131 | 22,721,313 | 1 | I | 20,221,222 | 20,230,202 | 2023-07-19 | 2023-07-19 | PER | null | US-OTSUKA-2023_000559 | OTSUKA | null | 75 | YR | null | F | Y | 92.1 | KG | 2023-07-19 | null | HP | US | US | 2023Q3 | 75 | Female | Health professional | Periodic | 92.1 |
231,355,101 | 23,135,510 | 1 | I | null | 20,231,018 | 2023-11-01 | 2023-11-01 | EXP | null | US-GRANULES-US-2023GRALIT00292 | GRANULES INDIA | Liz Rivera Blanco.Uncommon clinical manifestation after massive bupropion overdose: Ileus.Clinical Toxicology.JAN-2023;61 (Suppl. 2):92-93 | 16 | YR | T | F | Y | null | null | 2023-11-01 | null | HP | US | US | 2023Q4 | 16 | Female | Health professional | Expedited | null |
221,600,741 | 22,160,074 | 1 | I | 20,221,226 | 20,230,105 | 2023-03-31 | 2023-03-31 | 30DAY | null | AR-PFIZER INC-PV202300002708 | PFIZER | null | 12 | YR | null | F | Y | null | null | 2023-03-31 | null | MD | AR | AR | 2023Q1 | 12 | Female | Physician | 30DAY | null |
220,812,642 | 22,081,264 | 2 | F | null | 20,230,509 | 2023-03-09 | 2023-05-16 | EXP | null | US-BIOGEN-2023BI01192222 | BIOGEN | null | null | null | null | F | Y | null | null | 2023-05-16 | null | HP | US | US | 2023Q2 | null | Female | Health professional | Expedited | null |
225,875,301 | 22,587,530 | 1 | I | 20,230,101 | 20,230,608 | 2023-06-12 | 2023-06-12 | PER | null | US-AMGEN-USASP2023100341 | AMGEN | null | 59 | YR | A | F | Y | null | null | 2023-06-12 | null | CN | US | US | 2023Q2 | 59 | Female | Consumer | Periodic | null |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.